References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
See detailMéthodologie des essais cliniques et Notion d'Evidence Based Medicine
Bruyère, Olivier ULg

Learning material (2011)

Detailed reference viewed: 6 (1 ULg)
Full Text
See detailComplément d'épidémiologie
Bruyère, Olivier ULg

Learning material (2011)

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailMarkers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
Vasikaran, S.; Eastell, R.; Bruyère, Olivier ULg et al

in Osteoporosis International (2011), 22

Summary The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen ... [more ▼]

Summary The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies. Introduction Bone turnover markers (BTM) predict fracture risk, and treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. The aims of this report were to determine their clinical potential in the prediction of fracture risk and for monitoring the treatment of osteoporosis and to set an appropriate research agenda. Methods Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001. Results High levels of BTMs may predict fracture risk independently from bone mineral density in postmenopausal women. They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice. BTMs provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual. However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTM and by inadequate quality control. IOF/IFCC recommend one bone formation marker (s-PINP) and one bone resorption marker (s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine. Conclusion BTM hold promise in fracture risk prediction and for monitoring treatment. Uncertainties over their clinical use can be in part resolved by adopting international reference standards. [less ▲]

Detailed reference viewed: 58 (8 ULg)
Full Text
Peer Reviewed
See detailRelationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression
Rabenda, Véronique ULg; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2011), 22

Surrogate measures of fracture risk, such as effects on bone mineral density, may be of great interest to assess the efficacy of available osteoporosis treatments. Our results suggest that bone mineral ... [more ▼]

Surrogate measures of fracture risk, such as effects on bone mineral density, may be of great interest to assess the efficacy of available osteoporosis treatments. Our results suggest that bone mineral density (BMD) changes cannot be used as a surrogate of anti-fracture efficacy, among patients receiving calcium, with or without vitamin D. Introduction: The purpose of this study is to examine the association between changes in bone mineral density with reduction in the risk of fractures in patients receiving calcium with or without vitamin D. Methods: We selected all randomized placebo-controlled clinical trials of calcium with or without vitamin D supplementation. To be included in this analysis, the studies were required to report both BMD (hip/proximal femur and/or lumbar spine) and the incidence of fractures. Metaregression analyses were used to examine the associations of changes in BMD with reduction in risk of fracture over the duration of each study. The change in BMD was the difference between changes (from baseline) observed in the active treatment group and placebo group. Results: A total of 15 randomized trials (n=47,365) were identified, most of whom (77%) came from the Women’s Health Initiative trial. Results show that larger increases in BMD at the lumbar spine were not associated with greater reduction in fracture risk. Concerning hip BMD changes, we found a statistically significant relationship between hip BMD changes and reduction in risk. However, results were not quite significant after excluding the both largest studies, in which BMD changes were measured in very small subset of patients. These points may have largely biased our results. Conclusions: In conclusion, there was no evidence of a relationship between BMD changes and reduction in risk of fractures among patients receiving calcium with or without vitamin D supplementation. Calcium and/or Vitamin D may reduce fracture rates through a mechanism independent of bone density. [less ▲]

Detailed reference viewed: 37 (24 ULg)
Full Text
Peer Reviewed
See detailA FRAX(R) model for the assessment of fracture probability in Belgium.
Johansson, H.; Kanis, J. A.; McCloskey, E. V. et al

in Osteoporosis International (2011), 22(2), 453-61

A country-specific FRAX(R) model was developed from the epidemiology of fracture and death in Belgium. Fracture probabilities were identified that corresponded to currently accepted reimbursement ... [more ▼]

A country-specific FRAX(R) model was developed from the epidemiology of fracture and death in Belgium. Fracture probabilities were identified that corresponded to currently accepted reimbursement thresholds. INTRODUCTION: The objective of this study was to evaluate a Belgian version of the WHO fracture risk assessment (FRAX(R)) tool to compute 10-year probabilities of osteoporotic fracture in men and women. A particular aim was to determine fracture probabilities that corresponded to the reimbursement policy for the management of osteoporosis in Belgium and the clinical scenarios that gave equivalent fracture probabilities. METHODS: Fracture probabilities were computed from published data on the fracture and death hazards in Belgium. Probabilities took account of age, sex, the presence of clinical risk factors and femoral neck bone mineral density (BMD). Fracture probabilities were determined that were equivalent to intervention (reimbursement) thresholds currently used in Belgium. RESULTS: Fracture probability increased with age, lower BMI, decreasing BMD T-score and all clinical risk factors used alone or combined. The 10-year probabilities of a major osteoporosis-related fracture that corresponded to current reimbursement guidelines ranged from approximately 7.5% at the age of 50 years to 26% at the age of 80 years where a prior fragility fracture was used as an intervention threshold. For women at the threshold of osteoporosis (femoral neck T-score = -2.5 SD), the respective probabilities ranged from 7.4% to 15%. Several combinations of risk-factor profiles were identified that gave similar or higher fracture probabilities than those currently accepted for reimbursement in Belgium. CONCLUSIONS: The FRAX(R) tool has been used to identify possible thresholds for therapeutic intervention in Belgium, based on equivalence of risk with current guidelines. The FRAX(R) model supports a shift from the current DXA-based intervention strategy, towards a strategy based on fracture probability of a major osteoporotic fracture that in turn may improve identification of patients at increased fracture risk. The approach will need to be supported by health economic analyses. [less ▲]

Detailed reference viewed: 98 (37 ULg)
Full Text
See detailRehabilitation in osteoporosis
Bruyère, Olivier ULg

in Proceedings of the annual congress of the Royal Belgian Society of Physical and Rehabilitation medicine (2010, December)

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailCritères de retour sur le terrain
Delvaux, François ULg; Rochcongar, P.; Bruyère, Olivier ULg et al

in Abstract book du 7ème Congrès du GIBL (2010, November 27)

Detailed reference viewed: 102 (17 ULg)
Full Text
Peer Reviewed
See detailLe ranélate de strontium augmente la viabilité de chondrocytes humains stimulés par IL-1 bêta
Merville, Marie-Paule ULg; Deroyer, Céline ULg; Bruyère, Olivier ULg et al

in Revue du Rhumatisme (2010, November), 77(Suppl.3), 222

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailTrend of hip fracture incidence in Belgium between 2000 and 2007 and future projections
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Detilleux, Johann ULg et al

in Value in Health (2010, November), 13(7), 303

Detailed reference viewed: 34 (12 ULg)
Full Text
Peer Reviewed
See detailRelationship between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene
Bruyère, Olivier ULg; Detilleux, Johann ULg; Akadi, Chines et al

in Arthritis and Rheumatism (2010, October), 62(10), 406-407

Detailed reference viewed: 13 (9 ULg)
Full Text
Peer Reviewed
See detailHealth-related quality of life after total knee or hip replacement: a 7-year prospective study
Bruyère, Olivier ULg; Vanoverberghe, Marie ULg; Neuprez, Audrey ULg et al

in Annals of the Rheumatic Diseases (2010, June), 69(Suppl.3), 469

Detailed reference viewed: 36 (10 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg

in Therapeutic Advances in Musculoskeletal Disease (2010), 2(3), 133-143

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile, optimizing therapeutic adherence ... [more ▼]

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile, optimizing therapeutic adherence. Strontium ranelate is the first compound to simultaneously decrease bone resorption and stimulate bone formation. Its antifracture efficacy, at various skeletal sites, has been established up to 8 years, through studies of the highest methodological standards. Increases in bone mineral density, observed after 1 year of treatment, are predictive of the long-term fracture efficacy, hence suggesting, for the first time in osteoporosis, that bone densitometry can be used as a monitoring tool for both efficacy and compliance. Owing to a positive benefit/risk ratio, strontium ranelate may now be considered as a first-line treatment in the management of osteoporosis [less ▲]

Detailed reference viewed: 9 (2 ULg)